{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-129488","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.282420+00:00","generated_at":"2026-05-29T20:57:14.452486+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Korro Bio receives Australian clearance to begin Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency","bullets":["Australian HREC approval and TGA clearance obtained for Phase 1/2a REWRITE study of KRRO-110 in AATD.","First participant dosing expected Q1 2025; interim readout H2 2025; study completion anticipated 2026.","KRRO-110 aims to edit RNA to produce functional M-AAT; in mouse model, >60% editing achieved at therapeutically relevant levels.","Study will evaluate safety, tolerability, PK/PD of single and multiple ascending doses in PiZZ genotype patients."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-129488","json":"https://secwatch.observer/filing/0000950170-24-129488.json","markdown":"https://secwatch.observer/filing/0000950170-24-129488.md","text":"https://secwatch.observer/filing/0000950170-24-129488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024129488/0000950170-24-129488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024129488/krro-20241121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T20:57:14.452486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}